3,5--二氟苯甲酸甲酯 | 216393-55-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5--二氟苯甲酸甲酯
• 中文别名: 3,5-二氟苯甲酸甲酯
• 英文名称: methyl 3,5-difluorobenzoate
• CAS: 216393-55-4
• 化学式: C₈H₆F₂O₂
• mdl: MFCD01318160
• 分子量: 172.131
• InChiKey: JBEJPGWPXIIQBB-UHFFFAOYSA-N

物化性质

• 熔点：
  23-27 °C(lit.)
• 沸点：
  187-189 °C(lit.)
• 密度：
  1.265 g/mL at 25 °C(lit.)
• 闪点：
  170 °C
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R22,R36/38
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  保存方法：应存于密闭、阴凉、通风干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Methyl 3,5-difluorobenzoate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P362: Take off contaminated clothing and wash before reuse
P321: Specific treatment (see on this label)
P332+P313: If skin irritation occurs: Get medical advice/attention
P337+P313: If eye irritation persists get medical advice/attention

---

Section 3. Composition/information on ingredients.
Methyl 3,5-difluorobenzoate
Ingredient name:
CAS number: 216393-55-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6F2O2
Molecular weight: 172.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3,5-二氟苯甲酸甲酯是一种白色结晶状物质，主要用于合成蜕皮激素类杀虫剂如酰肼和甲氧虫酰肼的中间体。此外，它还能加速聚氨酯硬化过程，缩短脱模时间，并可用于合成阻燃剂。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3,5-二氟苯甲酸	3,5-difluorobenzoic acid	455-40-3	C7H4F2O2	158.104
  五氟苯甲酸甲酯	methyl pentafluorobenzoate	36629-42-2	C8H3F5O2	226.103
  2,3,4,5,6-五氟苯甲酸	Pentafluorobenzoic acid	602-94-8	C7HF5O2	212.076

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  3,5-二氟苯甲酸叔丁酯	tert-butyl 3,5-difluorobenzoate	467442-11-1	C11H12F2O2	214.212
  ——	2,6-difluoro-4-(methoxycarbonyl)benzoic acid	1415124-74-1	C9H6F2O4	216.141
  ——	methyl-4-(chlorocarbonyl) 3,5-difluoro-benzoate	1415124-75-2	C9H5ClF2O3	234.587

反应信息

• 作为反应物：
  描述：

  3,5--二氟苯甲酸甲酯 在 lithium aluminium deuteride 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 tert-butyl 4-((3,5-difluorophenyl)methyl-d2)piperazine-1-carboxylate
  参考文献：
  名称：

  Pyruvate kinase activators for use in therapy

  摘要：

  这里描述了使用激活丙酮酸激酶的化合物的方法。

  公开号：

  US09404081B2
• 作为产物：
  描述：

  五氟苯甲酸甲酯 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 、 N,N-二异丙基乙胺 作用下， 以 氘代苯 、 乙腈 为溶剂， 以92 %的产率得到3,5--二氟苯甲酸甲酯
  参考文献：
  名称：

  分子雕刻：通过苯甲酸盐的光催化加氢脱氟加快获得各种氟化芳烃的多用途工具

  摘要：

  从高度氟化的苯甲酸酯开始，我们开发了氟化苯甲酸芳基酯的定向光催化加氢脱氟 (HDF)，并展示了它与其他 HDF 策略的协同作用，以及 C-H 芳基化、脱羧偶联和脱羧质子化，以获得大多数氟化模式苯甲酸酯衍生物，并通过分子雕刻方法扩展苯衍生物。温和的反应条件和出色的区域选择性使该方法成为合成的理想选择。这种方法提供了从几种高度氟化的市售苯甲酸中获得 16 种具有不同氟化模式的苯甲酸酯衍生物的途径。我们为西格列汀、二氟尼柳和其他药学上重要的分子合成关键中间体或活性药物成分。重要的，我们提供了关于相对脱氟率和改变这些率的策略的重要见解。我们展示了 HDF 和相关技术的协同使用，以快速提高这些简单的商用全氟芳烃的合成复杂性，从而形成复杂的部分氟化分子。

  DOI：

  10.1021/acs.joc.2c02332

文献信息

• HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20140155398A1

  公开（公告）日：2014-06-05

  The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R 1 , R 2 and R 3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

  本发明提供了一种异环化合物，其化学式为（I），其药学上可接受的盐，其前药或水合物，其中A，A'，B，D，R1，R2和R3如本文所定义，包括一种以化合物（I）为活性成分的药物组合物，生产方法以及使用方法。特别是，本发明提供了一种化合物（I），用于治疗或预防与蛋白激酶相关的疾病，症状或紊乱，优选为Janus激酶家族。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• NOVEL KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20120225062A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

  本发明提供了如下式的化合物： 以及本文进一步描述的相关化合物，以及包含这些化合物的药物组合物。该发明还提供了使用这些化合物和组合物治疗与Pim激酶活性不良水平相关的疾病的方法，包括癌症和自身免疫性疾病。
• PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF
  申请人：Kawazoe Kentaro

  公开号：US20120178931A1

  公开（公告）日：2012-07-12

  Provided is a process by which pyrimidinylacetonitrile derivatives can be prepared easily and efficiently from industrially available raw materials. Also provided are intermediates for the synthesis of the derivatives. A process for the preparation of pyrimidinylacetonitrile derivatives represented by general formula (3) [wherein X is a halogen atom, and R is an alkoxymethyl group], characterized by reacting a 2,4-dihalogeno-6-nitrobenzene derivative represented by general formula (1) [wherein X and R are each as defined above] with 4,6-dimethoxy-2-cyanomethylpyrimidine represented by general formula (2) [wherein Me represents a methyl group] in the presence of a base; and intermediates for the synthesis of the pyrimidinylacetonitrile derivatives.

  提供了一种从工业可获得的原材料中轻松高效地制备嘧啶基乙腈衍生物的方法。还提供了合成这些衍生物的中间体。一种制备由通式（3）表示的嘧啶基乙腈衍生物的方法[其中X是卤素原子，R是烷氧甲基团]，其特征在于将由通式（1）表示的2,4-二卤代-6-硝基苯衍生物[其中X和R均如上定义]与由通式（2）表示的4,6-二甲氧基-2-氰基甲基嘧啶在碱的存在下反应；以及用于合成嘧啶基乙腈衍生物的中间体。
• [EN] HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2012160464A1

  公开（公告）日：2012-11-29

  The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

  本发明提供了一种异环化合物的化学式(I)，其药学上可接受的盐，其前药或水合物，其中A，A'，B，D，R1，R2和R3如本文所定义，包括一种化合物的药物组合物的化学式(I)作为活性成分，生产方法和使用方法。特别是，本发明提供了一种化合物的化学式(I)，用于治疗或预防与蛋白激酶相关的疾病，症状或紊乱，优选为Janus激酶家族。